ACCESS Newswire's 15min chart triggers bullish KDJ Golden Cross, Marubozu formation.

According to ACCESS Newswire's 15-minute chart, a golden cross of the KDJ indicator has been triggered at 16:00 on 08/15/2025. This bullish signal indicates a shift in the momentum of the stock price towards the upside, suggesting potential further increases. The presence of a bullish Marubozu candle further reinforces the notion of buyers dominating the market, which is likely to sustain the upward momentum.

According to ACCESS Newswire's 15-minute chart, a golden cross of the KDJ indicator was triggered at 16:00 on 08/15/2025. This bullish signal indicates a shift in the momentum of the stock price towards the upside, suggesting potential further increases. The presence of a bullish Marubozu candle further reinforces the notion of buyers dominating the market, which is likely to sustain the upward momentum.

The KDJ Golden Cross, observed on August 15, 2025, at 16:00, indicates a shift in momentum from bearish to bullish. The Bullish Marubozu pattern, characterized by candles with no upper or lower wicks, suggests strong buying pressure and a lack of selling pressure. This pattern, along with the KDJ Golden Cross, implies that buyers are in control of the market, and bullish momentum is likely to persist [1].

Investors should closely monitor Soligenix's financial announcements and earnings reports to assess the company's performance and potential impact on the stock price. Soligenix's recent developments in its late-stage therapy for cutaneous T-cell lymphoma (CTCL) highlight the company's potential for growth and innovation in the biopharmaceutical sector [2].

The recent advancements in Soligenix's HyBryte therapy for CTCL have generated significant interest among investors. The therapy has shown strong promise as a first-line treatment option for early-stage CTCL, with orphan drug designations in both the U.S. and Europe, as well as FDA Fast Track status. The therapy's use of synthetic hypericin activated by non-carcinogenic visible light offers a safer alternative to traditional treatments, which can take a year or more to show efficacy. The company's strong financial performance and positive analyst sentiment suggest that the stock is well-positioned for continued bullish momentum in the near term.

Institutional investors have also expressed confidence in Soligenix. The company recently declared a third-quarter 2025 dividend of $0.14 per share, payable on September 5, 2025 [3]. This dividend payout indicates strong financial performance and investor confidence in the company's future prospects.

References:
[1] https://www.ainvest.com/news/soligenix-15min-chart-shows-kdj-golden-cross-bullish-marubozu-formation-2508/
[2] https://www.morningstar.com/news/globe-newswire/9508825/networknewsaudio-announces-audio-press-release-apr-on-promising-first-line-therapy-for-rare-skin-cancer
[3] https://www.marketscreener.com/news/materion-corporation-declares-quarterly-cash-dividend-ce7c5ededa89f32d